AU2009330458B2 - Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders - Google Patents
Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders Download PDFInfo
- Publication number
- AU2009330458B2 AU2009330458B2 AU2009330458A AU2009330458A AU2009330458B2 AU 2009330458 B2 AU2009330458 B2 AU 2009330458B2 AU 2009330458 A AU2009330458 A AU 2009330458A AU 2009330458 A AU2009330458 A AU 2009330458A AU 2009330458 B2 AU2009330458 B2 AU 2009330458B2
- Authority
- AU
- Australia
- Prior art keywords
- auris
- agent
- composition
- formulation
- sensory cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14003308P | 2008-12-22 | 2008-12-22 | |
US61/140,033 | 2008-12-22 | ||
US16023309P | 2009-03-13 | 2009-03-13 | |
US61/160,233 | 2009-03-13 | ||
US16481209P | 2009-03-30 | 2009-03-30 | |
US61/164,812 | 2009-03-30 | ||
GB0907070.7 | 2009-04-24 | ||
GB0907070A GB2461962B (en) | 2008-07-25 | 2009-04-24 | Slow release NMDA receptor antagonist for otic disorders |
US17442109P | 2009-04-30 | 2009-04-30 | |
US61/174,421 | 2009-04-30 | ||
US12/504,553 US8496957B2 (en) | 2008-07-21 | 2009-07-16 | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
US12/504,553 | 2009-07-16 | ||
PCT/US2009/067552 WO2010074992A2 (en) | 2008-12-22 | 2009-12-10 | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2009330458A1 AU2009330458A1 (en) | 2010-07-01 |
AU2009330458B2 true AU2009330458B2 (en) | 2013-08-22 |
Family
ID=42288363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2009330458A Ceased AU2009330458B2 (en) | 2008-12-22 | 2009-12-10 | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2299976A4 (ja) |
JP (4) | JP6013736B2 (ja) |
CN (2) | CN106344495A (ja) |
AU (1) | AU2009330458B2 (ja) |
CA (1) | CA2732686C (ja) |
WO (1) | WO2010074992A2 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6170047B2 (ja) | 2011-08-31 | 2017-07-26 | ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド | アポトーシス−ターゲティングナノ粒子 |
ES2669561T3 (es) | 2012-02-17 | 2018-05-28 | University Of Georgia Research Foundation, Inc. | Nanopartículas para el transporte mitocondrial de agentes |
WO2015138992A1 (en) | 2014-03-14 | 2015-09-17 | University Of Georgia Research Foundation, Inc. | Mitochondrial delivery of 3-bromopyruvate |
AU2015296616A1 (en) * | 2014-07-29 | 2017-03-02 | Otonomy, Inc. | Otic formulations for the treatment of ceruminosis |
PE20181153A1 (es) | 2015-08-05 | 2018-07-17 | Childrens Medical Center | Composiciones con potenciadores de premiacion para suministro de farmacos |
JP7100866B2 (ja) | 2016-05-18 | 2022-07-14 | サウンド・ファーマシューティカルズ・インコーポレイテッド | メニエール病の処置法 |
JP7277360B2 (ja) * | 2016-09-14 | 2023-05-18 | ザ チルドレンズ メディカル センター コーポレーション | 薬物送達のための透過促進剤を有する組成物 |
MX2019003032A (es) * | 2016-09-16 | 2019-09-13 | Viking Therapeutics Inc | Metodo de reduccion de los efectos laterales asociados con la tiroides. |
KR20190104524A (ko) | 2016-11-21 | 2019-09-10 | 바이킹 테라퓨틱스 인코포레이티드 | 당원축적질환의 치료 방법 |
WO2018112815A1 (en) * | 2016-12-22 | 2018-06-28 | Nanjing University | Animal model for hearing loss syndrome and treatment method thereof |
KR102600115B1 (ko) | 2017-06-05 | 2023-11-09 | 바이킹 테라퓨틱스 인코포레이티드 | 섬유증 치료를 위한 조성물 |
EP3768690A4 (en) | 2018-03-22 | 2021-11-24 | Viking Therapeutics, Inc. | CRYSTALLINE SHAPES AND METHOD FOR MAKING CRYSTALLINE SHAPES OF A COMPOUND |
WO2020045162A1 (ja) * | 2018-08-30 | 2020-03-05 | 学校法人慶應義塾 | 薬物送達用担体 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5292516A (en) * | 1990-05-01 | 1994-03-08 | Mediventures, Inc. | Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0551626A1 (en) * | 1991-12-19 | 1993-07-21 | LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. | Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation |
WO2000007603A2 (en) * | 1998-08-04 | 2000-02-17 | Madash Llp | End modified thermal responsive hydrogels |
US6998137B2 (en) * | 2000-04-07 | 2006-02-14 | Macromed, Inc. | Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix |
US6589549B2 (en) * | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
EP1545551A4 (en) * | 2002-09-06 | 2008-10-22 | Durect Corp | DISTRIBUTION OF MODULATORS OF THE GLUTAMAT-MEDIATED NEUROTRANSMISSION TO THE INNER EAR |
US7589110B2 (en) * | 2002-09-06 | 2009-09-15 | Durect Corporation | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear |
US7220431B2 (en) * | 2002-11-27 | 2007-05-22 | Regents Of The University Of Minnesota | Methods and compositions for applying pharmacologic agents to the ear |
JP2005220070A (ja) * | 2004-02-05 | 2005-08-18 | Medgel Corp | 神経再生および保護のための生体吸収性高分子ハイドロゲル製剤 |
US8268866B2 (en) * | 2004-03-29 | 2012-09-18 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
US20060063802A1 (en) * | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
JP2006111585A (ja) * | 2004-10-15 | 2006-04-27 | Mebiol Kk | 徐放性組成物およびその徐放方法 |
JP2008531726A (ja) * | 2005-03-04 | 2008-08-14 | ニューロシステック コーポレイション | 改良されたガシクリジン製剤 |
EA017264B1 (ru) * | 2005-09-28 | 2012-11-30 | Аурис Медикаль Аг | Применение композиции арилциклоалкиламида для получения лекарственного препарата для лечения нарушения внутреннего уха |
TW200808360A (en) * | 2006-04-13 | 2008-02-16 | Alcon Mfg Ltd | RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions |
RU2499592C2 (ru) * | 2008-04-21 | 2013-11-27 | Отономи, Инк. | Фармацевтическая композиция для лечения ушных заболеваний |
MY161021A (en) * | 2008-05-14 | 2017-03-31 | Otonomy Inc | Controlled release corticosteroid and methods for the treatment of otic disorders |
-
2009
- 2009-12-10 EP EP09835529.0A patent/EP2299976A4/en not_active Withdrawn
- 2009-12-10 CN CN201610730867.1A patent/CN106344495A/zh active Pending
- 2009-12-10 CA CA2732686A patent/CA2732686C/en not_active Expired - Fee Related
- 2009-12-10 JP JP2011542272A patent/JP6013736B2/ja not_active Expired - Fee Related
- 2009-12-10 CN CN2009801305625A patent/CN102112111A/zh active Pending
- 2009-12-10 AU AU2009330458A patent/AU2009330458B2/en not_active Ceased
- 2009-12-10 WO PCT/US2009/067552 patent/WO2010074992A2/en active Application Filing
-
2015
- 2015-05-07 JP JP2015095099A patent/JP6207093B2/ja not_active Expired - Fee Related
-
2017
- 2017-04-26 JP JP2017087624A patent/JP2017160232A/ja active Pending
-
2018
- 2018-04-24 JP JP2018083451A patent/JP2018138585A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5292516A (en) * | 1990-05-01 | 1994-03-08 | Mediventures, Inc. | Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers |
Also Published As
Publication number | Publication date |
---|---|
JP2015164943A (ja) | 2015-09-17 |
CN102112111A (zh) | 2011-06-29 |
CA2732686C (en) | 2017-10-03 |
CA2732686A1 (en) | 2010-07-01 |
AU2009330458A1 (en) | 2010-07-01 |
WO2010074992A3 (en) | 2010-10-21 |
EP2299976A4 (en) | 2014-07-23 |
JP2018138585A (ja) | 2018-09-06 |
EP2299976A2 (en) | 2011-03-30 |
CN106344495A (zh) | 2017-01-25 |
JP2017160232A (ja) | 2017-09-14 |
WO2010074992A2 (en) | 2010-07-01 |
JP6207093B2 (ja) | 2017-10-04 |
JP2012513394A (ja) | 2012-06-14 |
JP6013736B2 (ja) | 2016-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9808460B2 (en) | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders | |
US10918594B2 (en) | Controlled-release CNS modulating compositions and methods for the treatment of otic disorders | |
AU2009330458B2 (en) | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders | |
US8399018B2 (en) | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders | |
US9427472B2 (en) | Controlled release compositions for modulating free-radical induced damage and methods of use thereof | |
JP5903119B2 (ja) | 耳の不調の治療用の制御放出性の抗菌性組成物および方法 | |
US10232044B2 (en) | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders | |
US8349353B2 (en) | Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders | |
EP2278999A2 (en) | Auris formulations for treating otic diseases and conditions | |
AU2020230269B2 (en) | Auris formulations for treating otic diseases and conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |